Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Satsuma Pharmaceuticals Inc (NQ: STSA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Satsuma Pharmaceuticals Inc

< Previous 1 2 3 Next >
Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite dropping around 60 points on Monday. 
Via Benzinga
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
STSA stock is dropping after Satsuma Pharmaceuticals reported that its lead migraine drug candidate failed to meet expectations. 
Via InvestorPlace
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping more than 100 points on Monday. 
Via Benzinga
Satsuma Pharma Shares Nosedives After Disappointing Data From Migraine Study
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
Expert Ratings for Satsuma Pharmaceuticals
Satsuma Pharmaceuticals (NASDAQ:STSA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
This Stock Earns Price Bump, Bullish Pitch On Recent Positive Migraine Drug Data
Via Benzinga
Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million. 
Via Benzinga
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday's Mid-Day Session
Gainers Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
Upgrades 
Via Benzinga
This Analyst Boosts Price Target On Satsuma Pharmaceuticals By 200%? Plus UBS Predicts $38 For General Motors
SVB Leerink raised the price target on Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) from $5 to $15. SVB Leerink analyst Marc Goodman upgraded the stock from Market Perform to Outperform. Satsuma... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target
Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal... 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 35 companies made new 52-week lows. 52-Week High And Low Highlights: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
40 Biggest Movers From Yesterday
Gainers Volcon, Inc. (NASDAQ: VLCN) shares jumped 97.5% to settle at $10.86 on Wednesday as the company priced its IPO at $5.50 per share. Voyager Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.